Robert Knight

21.9k total citations · 7 hit papers
204 papers, 12.6k citations indexed

About

Robert Knight is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Robert Knight has authored 204 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Hematology, 96 papers in Molecular Biology and 90 papers in Oncology. Recurrent topics in Robert Knight's work include Multiple Myeloma Research and Treatments (109 papers), Cancer Treatment and Pharmacology (51 papers) and Protein Degradation and Inhibitors (45 papers). Robert Knight is often cited by papers focused on Multiple Myeloma Research and Treatments (109 papers), Cancer Treatment and Pharmacology (51 papers) and Protein Degradation and Inhibitors (45 papers). Robert Knight collaborates with scholars based in United States, United Kingdom and Greece. Robert Knight's co-authors include Jerome B. Zeldis, Zhinuan Yu, Marta Olesnyckyj, Meletios Α. Dimopoulos, John J. Seaman, Dirk J. Reitsma, Joseph F. Simeone, John Patin, Allan Lipton and Alan F. List and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Robert Knight

201 papers receiving 12.2k citations

Hit Papers

Lenalidomide plus Dexamethasone for Relapsed or Refract... 1996 2026 2006 2016 2007 2007 2006 1996 1996 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
    2007 1.1k citations Meletios Α. Dimopoulos, Andrew Spencer et al. New England Journal of Medicine profile →
  2. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
    2007 925 citations Donna M. Weber, Christine Chen et al. New England Journal of Medicine profile →
  3. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
    2006 893 citations Alan F. List, Gordon W. Dewald et al. New England Journal of Medicine profile →
  4. Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
    1996 780 citations James R. Berenson, Alan Lichtenstein et al. New England Journal of Medicine profile →
  5. Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
    1996 772 citations Richard L. Theriault, Lester Porter et al. New England Journal of Medicine profile →
  6. Efficacy of Lenalidomide in Myelodysplastic Syndromes
    2005 613 citations Alan F. List, Robert Knight et al. New England Journal of Medicine profile →
  7. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
    2017 392 citations Zhinuan Yu, Robert Knight et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Knight United States 45 7.9k 6.5k 6.2k 1.9k 1.3k 204 12.6k
Peter I. Croucher United Kingdom 55 2.2k 0.3× 5.6k 0.9× 4.3k 0.7× 372 0.2× 1.2k 0.9× 189 9.8k
E. A. McCulloch Canada 58 7.5k 0.9× 3.6k 0.6× 5.8k 0.9× 3.4k 1.8× 2.4k 1.8× 206 16.5k
Harland N. Sather United States 64 4.7k 0.6× 2.3k 0.4× 2.8k 0.4× 1.3k 0.7× 143 0.1× 188 13.1k
Charlotte M. Niemeyer Germany 54 4.8k 0.6× 1.6k 0.2× 4.1k 0.7× 1.8k 0.9× 233 0.2× 260 10.3k
Stephen D. Nimer United States 64 6.8k 0.9× 3.4k 0.5× 7.5k 1.2× 2.8k 1.4× 217 0.2× 239 14.6k
Gordon W. Dewald United States 57 7.7k 1.0× 2.3k 0.4× 4.4k 0.7× 5.2k 2.7× 336 0.3× 212 13.1k
Brigitte Schlegelberger Germany 66 6.7k 0.8× 2.9k 0.5× 7.8k 1.2× 3.7k 1.9× 206 0.2× 395 16.3k
Stefan Suciu Belgium 54 3.3k 0.4× 4.7k 0.7× 3.5k 0.6× 835 0.4× 251 0.2× 235 9.5k
Alessandro M. Gianni Italy 44 1.7k 0.2× 3.7k 0.6× 2.1k 0.3× 3.4k 1.8× 463 0.3× 205 9.4k
Marco Bregni Italy 45 3.8k 0.5× 4.7k 0.7× 2.0k 0.3× 1.6k 0.8× 573 0.4× 193 10.0k

Countries citing papers authored by Robert Knight

Since Specialization
Citations

This map shows the geographic impact of Robert Knight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Knight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Knight more than expected).

Fields of papers citing papers by Robert Knight

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Knight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Knight. The network helps show where Robert Knight may publish in the future.

Co-authorship network of co-authors of Robert Knight

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Knight. A scholar is included among the top collaborators of Robert Knight based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Knight. Robert Knight is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Warburton, Fiona, et al.. (2023). Migration and differentiation of muscle stem cells are coupled by RhoA signalling during regeneration. Open Biology. 13(9). 230037–230037. 2 indexed citations
4.
Klein‐Nulend, Jenneke, Astrid D. Bakker, Jianfeng Jin, et al.. (2021). Myofiber stretch induces tensile and shear deformation of muscle stem cells in their native niche. Biophysical Journal. 120(13). 2665–2678. 21 indexed citations
5.
Mitchell, C. A., José Alonso Solís-Lemus, Constantino Carlos Reyes‐Aldasoro, et al.. (2020). Cell Tracking Profiler – a user-driven analysis framework for evaluating 4D live-cell imaging data. Journal of Cell Science. 133(22). 4 indexed citations
6.
Moyle, Louise A., Eric Blanc, Oihane Jaka, et al.. (2016). Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy. eLife. 5. 22 indexed citations
7.
Zangari, Maurizio, Guido Tricot, Fenghuang Zhan, et al.. (2009). Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone. Journal of Clinical Oncology. 28(1). 132–135. 44 indexed citations
8.
Szende, Ágota, Caroline Schaefer, Thomas F. Goss, et al.. (2009). Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health and Quality of Life Outcomes. 7(1). 81–81. 42 indexed citations
9.
Stadtmauer, Edward A., Donna M. Weber, Rubén Niesvizky, et al.. (2009). Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. European Journal Of Haematology. 82(6). 426–432. 82 indexed citations
10.
Wang, Michael, Meletios Α. Dimopoulos, Christine Chen, et al.. (2008). Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 112(12). 4445–4451. 135 indexed citations
11.
Andritsos, Leslie A., Amy J. Johnson, Gerard Lozanski, et al.. (2008). Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 26(15). 2519–2525. 117 indexed citations
12.
Knight, Robert, Katharina Mebus, & Henry Roehl. (2008). Mandibular arch muscle identity is regulated by a conserved molecular process during vertebrate development. Journal of Experimental Zoology Part B Molecular and Developmental Evolution. 310B(4). 355–369. 19 indexed citations
13.
Baz, Rachid, Esteban Walker, Mohamed A. Karam, et al.. (2006). Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology. 17(12). 1766–1771. 116 indexed citations
14.
List, Alan F., Gordon W. Dewald, John M. Bennett, et al.. (2006). Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. New England Journal of Medicine. 355(14). 1456–1465. 893 indexed citations breakdown →
15.
Jones, Richard W., Robert Knight, Sal Rassam, et al.. (2003). An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma.. Blood. 102(11). 7 indexed citations
16.
Knight, Robert, et al.. (2000). An amphioxus Krox gene: insights into vertebrate hindbrain evolution. Development Genes and Evolution. 210(10). 518–521. 28 indexed citations
17.
Lipton, Allan, L. Demers, Vernon M. Chinchilli, et al.. (1998). Markers of bone resorption in patients treated with pamidronate. European Journal of Cancer. 34(13). 2021–2026. 126 indexed citations
18.
Berenson, James R., Alan Lichtenstein, Lester Porter, et al.. (1996). Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma. New England Journal of Medicine. 334(8). 488–493. 780 indexed citations breakdown →
19.
Wright, DG, Diane L. Lucas, Robert Knight, et al.. (1992). Metabolic events that promote the terminal maturation of hematopoietic progenitor cells. Experimental Hematology. 20(1). 141–142. 2 indexed citations
20.
Griffin, J D, Steven Kessler, Mary A. Cutting, et al.. (1992). Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.. PubMed. 20(4). 442–8. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter I. Croucher Breakdown of academic impact, for papers by E. A. McCulloch Breakdown of academic impact, for papers by Harland N. Sather Breakdown of academic impact, for papers by Charlotte M. Niemeyer Breakdown of academic impact, for papers by Stephen D. Nimer Breakdown of academic impact, for papers by Gordon W. Dewald Breakdown of academic impact, for papers by Brigitte Schlegelberger Breakdown of academic impact, for papers by Stefan Suciu Breakdown of academic impact, for papers by Alessandro M. Gianni Breakdown of academic impact, for papers by Marco Bregni
Rankless by CCL
2026